Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | DHCR7 | Q9UBM7 | 3/20 | 0.34 |
| ▸ | EBP | Q15125 | 2/20 | 0.34 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21161986 | 0.86 | KDM2B (0.31) | — | |
| SCHEMBL20259924 | 0.86 | KDM2B (0.31) | — | |
| SCHEMBL25091210 | 0.86 | KDM2B (0.31) | — | |
| SCHEMBL18664075 | 0.84 | KDM4E (0.35) | KDM4EPOLBDHCR7EBP | |
| SCHEMBL18664081 | 0.84 | KDM4E (0.35) | KDM4EPOLBDHCR7EBP | |
| SCHEMBL21349513 | 0.83 | KDM4E (0.33) | KDM4EPOLBDHCR7MEN1KMT2A | |
| SCHEMBL18664079 | 0.81 | TLR9 (0.34) | KDM4EPOLBDHCR7EBPALDH1A1 | |
| SCHEMBL18664071 | 0.81 | TLR9 (0.34) | KDM4EPOLBDHCR7EBPALDH1A1 | |
| SCHEMBL18664072 | 0.81 | TLR9 (0.34) | KDM4EPOLBDHCR7EBPALDH1A1 | |
| SCHEMBL20757584 | 0.79 | MAP3K12 (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023217879-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| WO-2023142754-A1 | EZH1/2 INHIBITOR, PREPARATION THEREOF, AND USE THEREOF IN ANTI-TUMOR THERAPY | 江苏天士力帝益药业有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-9115140-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| EP-2593455-B1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-03-18 | — | — | EP | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013150036-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2013-10-10 | — | — | WO | disclosed |
| US-20130261106-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2013-10-03 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130060020-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | KDM4E 3481/4885POLB 2260/4885DHCR7 2337/4885 |
| US-20130060020-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, SMN1; SMN2 | KDM4E 2398/4885POLB 3704/4885DHCR7 878/4885 |
| US-20130261106-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | KDM4E 3418/4885POLB 708/4885DHCR7 454/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | KDM4E 4659/4885POLB 3902/4885DHCR7 694/4885 |
| US-20230278989-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | KDM4E 3104/4885POLB 874/4885DHCR7 2217/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | KDM4E 2333/4885POLB 660/4885DHCR7 254/4885 |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | KDM4E 3949/4885POLB 200/4885DHCR7 2886/4885 |
| US-20250197402-A1 | Tyrosine Kinase Inhibitors | BTK, LYN, SYK | KDM4E 1390/4885POLB 1806/4885DHCR7 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.